Thymomas and thymic carcinomas (constituting the thymic epithelial tumours [TETs]) are rare epithelial tumours. There are limited treatment options for patients with advanced TETs. The complexity and rarity of the disease hampers the development of effective therapeutics. Next-generation sequencing (NGS) of TETs has confirmed the very low mutational burden and few actionable targets for therapy. Thus, novel strategies are needed for better elucidating the molecular pathways involved in tumour pathogenesis and identification of novel drug targets.
Guha et al. hypothesised that a global proteomics approach may elucidate altered signalling pathways in TETs that can be potentially targeted. To investigate this, 3-state SILAC quantitative mass spectrometry was used to characterise the global proteome and phosphoproteome of TETs, aiming to identify potential actionable drivers in thymomas and thymic carcinomas. Two thymoma (IU-TAB1 and T1682) and three thymic ca...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Promising Phase 1 Results of Novel Kras-inhibitor in NSCLC Next Article
Novel ways to assess MS »
Table of Contents: WCLC 2019
Screening, Detection, and Diagnosis
Non-Small-Cell Lung Cancer
Other Thoracic Malignancies
Phase 3 Trial Updates
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.